Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Doxorubicin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 04 Jun 2024 Results (n=574) 9 investigating the efficacy of atezo in combination with bev and non-platinum-based chemo , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 25 Jul 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2024.
- 25 Jul 2022 Status changed from recruiting to active, no longer recruiting.